Collegium Pharmaceutical Inc

COLL

Company Profile

  • Business description

    Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

  • Contact

    100 Technology Center Drive
    StoughtonMA02072
    USA

    T: +1 781 713-3699

    E: [email protected]

    https://www.collegiumpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    357

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.7056.700.65%
CAC 407,738.4275.830.99%
DAX 4023,790.11116.820.49%
Dow JONES (US)44,484.4210.52-0.02%
FTSE 1008,774.6910.64-0.12%
HKSE24,221.41149.130.62%
NASDAQ20,393.13190.240.94%
Nikkei 22539,762.48223.85-0.56%
NZX 50 Index12,784.2949.760.39%
S&P 5006,227.4129.400.47%
S&P/ASX 2008,597.7056.600.66%
SSE Composite Index3,454.792.95-0.09%

Market Movers